Digital MSK Europe: Leading HealthTech companies to watch in 2026

Nelson Advisors
8 hours ago
13 min read

Executive Summary: The Dawn of a Data-Driven MSK Revolution

The European digital health market is at a pivotal inflection point, with the musculoskeletal (MSK) sector emerging as a primary frontier for innovation and investment. This market is not merely growing; it is undergoing a fundamental transformation, driven by an aging demographic, the increasing prevalence of chronic conditions, and a critical shift towards data-enabled, value-based care. The European Digital MSK market is projected to reach a revenue of US$3.28 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.1% from 2025 to 2030.

This regional expansion is a significant component of the broader global digital health market, which is advancing at a resilient CAGR of 23.6% for the same period.The immense capital and strategic focus flowing into this sector are creating a new era of competition defined by a strategic clash between well-funded U.S. healthtech titans and clinically-validated European native companies.

For a company to emerge as a leader in 2026, its success will depend on more than just technological prowess or financial backing. The ability to navigate the intricate and evolving European regulatory and reimbursement landscape is paramount. The analysis presented herein identifies three core competencies that will serve as predictive factors for market leadership: a proven capacity for securing national reimbursement, particularly through Germany's pioneering Digital Health Applications (DiGA) framework; a foundation of extensive, peer-reviewed clinical evidence that demonstrates both efficacy and cost-effectiveness; and a strategic adaptability that allows for success within Europe's fragmented payer systems, either through a localised, integrated approach or by leveraging global scale to address multi-national clients. The companies poised for success in 2026 are those that have already demonstrated a mastery of these principles, establishing a clear path from innovation to sustainable, scalable market presence.

The European Digital MSK Market: Growth Drivers and Strategic Context

The digital musculoskeletal health market in Europe is in a phase of dynamic expansion, fueled by strong underlying demand and significant technological advancements. A detailed analysis of the market's quantitative outlook, shifting care models, and strategic benchmarks reveals the key dynamics that will shape the competitive landscape in 2026 and beyond.

Market Size, Segmentation, and Forecast for 2026

The market for digital health solutions in musculoskeletal care is growing at a remarkable pace. In 2024, the European market generated a revenue of US1.22billion. Projections indicate a substantial increase, with the market forecast to reach $US3.28 Billion by 2030, representing a healthy CAGR of 18.1% from 2025 to 2030. This growth trajectory underscores the increasing acceptance and adoption of digital solutions by patients, providers, and payers across the continent.

An examination of the market's components reveals a significant strategic evolution. In 2024, the "software & services" segment was the largest revenue generator. However, the market highlights identify "hardware" as the most lucrative component, positioned to register the fastest growth during the forecast period. This seemingly paradoxical trend is, in fact, a critical indicator of the market's maturity. The initial wave of digital MSK solutions was predominantly app-based, relying on pure software to deliver care. The next phase of maturity, which will be prominent in 2026, involves more sophisticated, connected hardware such as motion sensors and wearable devices. Companies that can successfully integrate these components will be best positioned to capture this high-growth hardware segment, thereby creating a strategic moat against purely software-based competitors. This also enhances the clinical rigour and data collection capabilities of a solution, which is non-negotiable for securing national reimbursement and demonstrating quantifiable value to payers.

From a regional perspective, the market's growth is not uniform. While the United Kingdom, Germany, and France represent major markets, data indicates that Denmark is expected to register the highest CAGR from 2025 to 2030. This suggests a market uniquely receptive to digital health solutions, possibly due to a supportive regulatory environment, high digital adoption rates, or an advanced healthcare system that is already embracing technology-enabled care models. For companies seeking to expand, Denmark may serve as a strategic entry point or a benchmark for success in other countries.

Shifting Care Models and Demand Drivers

The demand for digital MSK solutions is driven by a confluence of macroeconomic and healthcare-specific trends. Globally, the overarching digital health market is expanding due to a rising geriatric population and the subsequent increase in the prevalence of chronic illnesses. This trend directly applies to MSK conditions, as ailments like back pain and osteoarthritis are chronic and highly prevalent in older populations.

In response, healthcare models are rapidly shifting away from purely in-person care towards virtual and hybrid solutions. A survey of U.S. employers provides a glimpse into this future, with 96% of respondents indicating they will offer or are considering offering virtual MSK treatments in 2026/2027. This trend is directly influencing the European market as U.S.-based companies, such as Hinge Health, are launching global solutions to serve their multinational clients.

A critical element of this evolution is the ascendance of the hybrid care model. As exemplified by the U.S.-based Limber Health, this model seeks to augment, rather than replace, in-person care with digital tools. By combining in-clinic treatment with digital support for remote therapeutic monitoring (RTM) and home exercise programs, this approach is more palatable and scalable in European healthcare systems, which are often cautious of purely virtual-first models that might bypass traditional providers. It positions digital health companies as strategic partners to existing physical therapists, physicians, and payers, which is a key to gaining widespread adoption and overcoming historical resistance to change.

Europe Digital Health for Musculoskeletal Care Market Outlook

Data Point	Value	Context
Europe Market Revenue (2024)	US$1.224 Billion	Historical revenue base for market analysis.
Europe Market Forecast (2030)	US$3.287 Billion	Future projected market size.
Europe Market CAGR (2025-2030)	18.1%	Annual growth rate.
Largest Component (2024)	Software & Services	Primary revenue driver in recent period.
Fastest Growing Component (2025-2030)	Hardware	Indicative of future market maturation and shift toward connected devices.
Key Country for CAGR	Denmark	Expected to lead regional growth.

Navigating the European Healthtech Regulatory & Reimbursement Maze

The European market is not a single entity but a collection of diverse national healthcare systems, each with its own regulatory and reimbursement pathways. A company's success in this environment is directly tied to its ability to navigate this complexity. Germany's pioneering DiGA framework provides a strategic blueprint, while broader EU regulations like the EHDS and HTAR are creating a new, data-centric framework for future competition.

Germany's DiGA Framework: A Golden Standard for Reimbursement

Germany’s DiGA (Digitale Gesundheitsanwendungen) framework is a revolutionary legislative initiative that has officially integrated digital health applications into mainstream medical care. Colloquially known as "apps on prescription," DiGAs can be prescribed by physicians and reimbursed by statutory health insurers, covering approximately 90% of the German population. This framework is the world's first structured pathway for prescribable health apps at scale and provides a powerful precedent for other European countries.

A key element of this framework is the "Fast-Track" approval process, managed by the Federal Institute for Drugs and Medical Devices (BfArM). This process allows a manufacturer to receive a provisional listing for a trial phase of up to 12 months, during which the app can be prescribed and reimbursed. This trial period is used to collect the necessary real-world evidence to demonstrate a "positive care effect" for permanent listing. The success of this model is undeniable: the number of approved DiGAs grew from 24 at the end of 2021 to 68 by late 2024, with cumulative reimbursements reaching €234 million. This process is more than a single market entry; it is a critical regulatory "boot camp" that proves a company's product is a true medical device with verified efficacy and security. For other European countries, a DiGA listing serves as a powerful de facto endorsement, making it a crucial strategic milestone.

The Broader EU Regulatory Landscape: EHDS and HTAR

Beyond Germany, two major regulatory developments are shaping the future of digital health across the European Union. On January 21, 2025, the European Health Data Space Regulation (EHDS) was formally adopted. The EHDS has two primary goals: to improve individuals' access to their electronic health data and to enable the secure, mandatory sharing of this data for secondary purposes, such as research and the training of high-risk AI systems. While the provisions for secondary use will become applicable from 2029, companies holding health data must begin preparing their technical infrastructure and data governance policies now. The EHDS creates a new competitive dynamic where a company's ability to securely manage and leverage this data will become a core business competency.

Simultaneously, the Health Technology Assessment Regulation (HTAR), which aims to harmonise the evaluation of new health technologies, will begin its joint clinical assessments in 2026. This regulation will standardize the criteria for evaluating the clinical and cost-effectiveness of new technologies, providing a clear, evidence-based pathway for innovators. The convergence of EHDS and HTAR signals that the future "moat" for digital health companies will be defined not just by technological innovation, but by their capacity to successfully navigate this increasingly harmonised and data-centric regulatory environment.

Country-Specific Models: The Fragmented UK Approach

In contrast to Germany’s unified framework, the United Kingdom presents a more fragmented reimbursement landscape. There is no single, mandatory pathway for reimbursement, and digital solutions are not widely available on prescription. Instead, adoption and reimbursement decisions are managed locally by regional National Health Service (NHS) bodies known as Integrated Care Systems (ICSs). While the National Institute for Health and Care Excellence (NICE) provides an evidence standards framework to guide the procurement of digital health technologies, this guidance is not directly linked to reimbursement, which can disincentivize robust evidence generation. This fragmented approach requires companies to forge individual contracts and partnerships at the regional level, highlighting a need for a highly localised go-to-market strategy to succeed in the UK.

The European Regulatory Landscape for Digital Health

Regulation Name	Purpose/Key Function	Governing Body	Scope	Effective Date
DiGA (Germany)	Reimbursement for prescribable digital health apps.	Federal Institute for Drugs and Medical Devices (BfArM)	Germany-specific	In effect since 2019.
EHDS (EU)	Harmonized framework for primary and secondary use of health data.	Health Data Access Bodies (HDABs)	EU-wide	Adopted 2025; secondary use applicable 2029/2031.
HTAR (EU)	Harmonized clinical assessment of health technologies.	European Commission, Member States	EU-wide	Joint clinical assessments begin 2026.

The Leaders of 2026: Companies to Watch

The competitive landscape in 2026 is defined by a strategic contest between a few well-capitalized global players and a select number of clinically-validated European natives. The following analysis profiles the companies best positioned to lead this market.

Kaia Health: The Clinically Validated European Native

Kaia Health, with its dual headquarters in Munich and New York, stands out as a leading European player with a clear, localised strategy. The company has raised $125 million, a sum that, while significant, is a fraction of the funding secured by its U.S. counterparts. Despite this difference in scale, the company has executed a highly effective strategy centred on clinical rigour and regulatory success.

Kaia Health's core technological offering is its AI-powered computer vision, branded as Motion Coach. This proprietary technology provides real-time, physical therapy-grade feedback on exercises using only a smartphone or tablet camera, with no additional sensors or wearables required. This no-hardware approach enhances accessibility and user convenience. The product itself is based on multimodal rehabilitation (MMR), an evidence-based approach that combines guided exercises with relaxation practices and pain education, which is the international gold-standard for chronic pain management.

The company's position as a leader is built on a foundation of robust clinical evidence. Kaia Health is described as one of the most clinically validated digital MSK providers. The company conducted the industry's largest randomised controlled trial (Rise-uP), which demonstrated an 80% reduction in costs compared to standard-of-care treatments. A separate study also validated its AI's accuracy, showing it can provide exercise feedback as accurately as a human physical therapist.

However, the most critical differentiator for Kaia Health is its proven ability to navigate the European regulatory landscape. The company has secured a DiGA listing in Germany for its chronic back pain app and its COPD app. This achievement is a testament to its commitment to clinical excellence and its strategic focus on securing a direct reimbursement pathway. By obtaining the DiGA "golden seal" of approval, Kaia Health has de-risked its model and established a powerful proof point that will be invaluable for convincing payers and providers in other countries to adopt its solution. The company has stated its intent to use this success to expand its solutions through national reimbursement systems across Europe.

The U.S. Titans: Hinge Health & Sword Health

While European natives like Kaia Health are carving out a strategic niche, U.S.-based giants Hinge Health and Sword Health are leveraging their global scale and immense funding to penetrate the European market.

Hinge Health: With over $854 million in funding, Hinge Health IPO'd in May 2025 and has a valuation of $6.2 billion as of late 2021. The company's European market strategy is centred on its "Global" solution, which offers personalised and accessible care to members outside the U.S. through a single app. This approach primarily targets multinational employers and health plans, aiming to leverage existing relationships to build a presence in Europe. The Hinge Health platform combines expert clinical care with a comprehensive clinical team and utilises both advanced computer vision and wearable sensors. Its clinical evidence includes a peer-reviewed study showing a 73% reduction in acute pain.

Sword Health: Founded in Portugal, Sword Health now has a significant presence in the U.S. and Europe, with $450 million in funding and a $3 billion valuation as of late 2021. Sword’s model pairs AI with licensed clinicians and relies on wearable motion sensors. The company boasts an extensive body of clinical research, with over 40 peer-reviewed papers. A key differentiator for Sword is its explicit focus on health equity. Its research demonstrates that its solution delivers high engagement and stellar clinical outcomes in diverse populations, regardless of their location, race, or socioeconomic background.

Emerging Local Innovators & Niche Players

The European market is not a winner-take-all environment. Smaller, localized innovators demonstrate alternative, successful strategies. A notable example is getUBetter from the UK. The company has developed a self-management app for common MSK conditions that is integrated with and offered by local NHS clinical teams and GPs.

This model, which is tailored to specific country-level health systems, proves that success can be achieved by working within the existing healthcare infrastructure rather than attempting a large-scale disruption. Other promising startups, such as Cure Bionics (Tunisia), which focuses on 3D-printed bionic arms, and Horus ML (Spain), which uses AI for cardiovascular risk detection, indicate a rich ecosystem of innovation beyond core MSK pain management.

Table 3: Comparative Analysis of Leading Digital MSK Companies

Feature	Kaia Health	Hinge Health	Sword Health
Total Funding	$125 million	$854 million	$450 million
Latest Valuation / IPO Status	Undisclosed	$6.2B (2021) / IPO May 2025	$3B (2021)
Primary Headquarters	New York, Munich	San Francisco	New York, Lisbon
Technology	AI Computer Vision (No sensors)	Computer Vision + Wearables	AI + Wearable Sensors
European Market Strategy	Focus on national reimbursement (DiGA)	Global solution for multinational employers	International expansion via employer/health plan partnerships
Clinical Evidence Highlights	Largest RCT (80% cost reduction); AI accuracy on par with PTs	Peer-reviewed studies on pain reduction	40+ peer-reviewed papers; focus on health equity
European Regulatory Successes	DiGA listing for MSK and COPD apps	None mentioned	MDR CE Mark

Future Outlook and Strategic Recommendations for 2026

The analysis of the European digital MSK landscape in 2026 reveals a market on the verge of significant consolidation and strategic realignment. For investors, payers, and industry stakeholders, a nuanced understanding of these dynamics is crucial for making informed decisions.

Investment & Partnership Opportunities

Companies with a proven track record of navigating European regulatory frameworks represent de-risked investment opportunities. For instance, a company that has successfully secured a DiGA listing in Germany, such as Kaia Health, has demonstrated its ability to achieve a clear, established path to reimbursement. This strategic focus is often a more capital-efficient path to market than a high-spend, global-scale approach. As a result, such companies are likely to attract significant investment and partnership interest.

Beyond direct-to-patient solutions, a promising area for investment lies in "enabler" companies that facilitate the hybrid care model. Solutions that provide software for existing providers, as exemplified by the U.S.-based Limber Health, are highly likely to gain traction in Europe. This approach aligns with the cautious nature of many European healthcare systems by working with, rather than against, existing infrastructure. The formal adoption of the EHDS also signals that companies specialising in secure health data management and AI development for clinical applications will be highly valuable acquisition targets, as their expertise will be essential for navigating the complex data-sharing requirements of the future.

Key Success Factors for 2026 and Beyond

The future leaders of the European digital MSK market will share several key characteristics that go beyond their initial funding or brand recognition.

Regulatory First: A company's success in Europe will be determined by its regulatory strategy before its product is even launched. A clear reimbursement pathway is non-negotiable for achieving widespread adoption. The achievement of a CE Mark and, most importantly, a DiGA listing, serves as the ultimate proof of a company's regulatory and clinical maturity.
Evidence-Based Value Proposition: The emphasis from payers and health systems will increasingly be on quantifiable outcomes and demonstrable cost savings. The impressive claims of Kaia Health regarding an 80% cost reduction and the focus of Vori Health on impacting key health quality measures like HEDIS are not just marketing points; they are essential components of a successful value proposition.
Localisation and Interoperability: A one-size-fits-all approach will fail in a region with such diverse healthcare systems. Leaders in 2026 will have localised content, multilingual support, and the ability to seamlessly integrate with existing EHR systems and care models. The success of a company like getUBetter, which is deeply embedded in local NHS services, demonstrates the power of a localised, interoperable approach.

In conclusion, the European digital MSK market in 2026 will be defined by a new level of maturity. Success will not be measured by the size of a company's war chest but by its ability to demonstrate a clear return on investment, backed by robust clinical evidence and a well-defined regulatory and reimbursement strategy. The companies to watch are those that have already begun building these foundational competencies, positioning themselves as indispensable partners to the continent’s healthcare systems.

Nelson Advisors > HealthTech and MedTech M&A

Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide